Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2020 | Sinusoidal obstruction syndrome in patients with R/R B-cell ALL

Valentín Ortiz-Maldonado • 1 Sep 2020
EBMT 2020
Acute Lymphoblastic Leukemia Leukemia CAR-T Inotuzumab ozogamicin Varnimcabtagene autoleucel

Valentín Ortiz-Maldonado, MD, Hospital Clínic de Barcelona, Barcelona, Spain, discusses sinusoidal obstruction syndrome in patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (ALL) treated with ARI-0001 cells (varnimcabtagene autoleucel). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Valentín Ortiz-Maldonado

A “dose-dense” approach to CAR-T administration in a trial investigating JCAR014 in B-cell lymphoma 3:34
A “dose-dense” approach to CAR-T administration in a trial investigating JCAR014 in B-cell lymphoma
Valentín Ortiz-Maldonado • 7 Feb 2025
Results of the pivotal CART19-BE-02 trial, a multicenter trial of var-cel for adult R/R B-ALL 5:24
Results of the pivotal CART19-BE-02 trial, a multicenter trial of var-cel for adult R/R B-ALL
Valentín Ortiz-Maldonado • 7 Feb 2025
Optimizing preceding and consolidation therapies to prevent post-CAR-T relapse in B-ALL 2:46
Optimizing preceding and consolidation therapies to prevent post-CAR-T relapse in B-ALL
Valentín Ortiz-Maldonado • 16 Apr 2024
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter’s transformation 3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter’s transformation
Valentín Ortiz-Maldonado • 16 Apr 2024

Related Videos

The value and mission of the International Workshop on Acute Leukemias 14:36
The value and mission of the International Workshop on Acute Leukemias
Charles Craddock et al. • 21 Oct 2025
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years? 1:30
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years?
Koichi Takahashi • 26 Sep 2025
One big question with Naval Daver: what AML advance could transform frontline care in three years? 1:05
One big question with Naval Daver: what AML advance could transform frontline care in three years?
Naval Daver • 26 Sep 2025
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years? 3:13
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years?
Charles Craddock • 26 Sep 2025
The content of VJHemOnc is intended for healthcare professionals